Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, A meeting of the Subject Expert Committee (SEC) of the <keyword id="170943" type="COMPANY" weightage="20" keywordseo="Central-Drugs-Standard-Control-Organisation">Central Drugs Standard Control Organisation</keyword> (CDSCO) is currently underway to discuss the permission sought by vaccine developer <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> to conduct <keyword id="83911" type="ORGANIZATION" weightage="20" keywordseo="Clinical-trials">clinical trials</keyword> of its <keyword id="9985444" type="UNKNOWN" weightage="20" keywordseo="intranasal-vaccine">intranasal vaccine</keyword> for the <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword>. Days after getting the Drugs Controller General of India's nod for restricted emergency use of India's first indigenously-made <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>, Bharat Biotech had applied to the drug regulator for permission to start Phase 1 and 2 trials of their nasal coronavirus vaccine. The nasal vaccine is different from the intramuscular vaccine which recently got approval, as it is non-invasive, needle-free, doesn't require trained healthcare workers, eliminates needle-associated risks, suits children and adults and has scalable manufacturing. Clinical trials of Bharat Biotech's 'BBV154' - a novel adenovirus vectored intranasal vaccine for coronavirus -- will be conducted at various locations, a top source privy to the development told IANS. The vaccine will be single-dosed. According to the firm, an intranasal vaccine stimulates a broad immune response at the site of infection, in the nasal mucosa, which is essential for blocking both infection and transmission of Covid-19. The vaccine has demonstrated protective efficacy in mice and hamsters. Mice and hamsters immunised with its single-dose were conferred superior protection against SARS-CoV-2 challenge, "more so than one or two intramuscular immunisations of the same vaccine and dose". "Thus, intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus, thereby protecting against disease, infection and transmission," Bharat Biotech said in a statement. On January 3, two intramuscular vaccines - Bharat Biotech's Covaxin and Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India - were approved for restricted emergency use and have been administered to over three lakh people till now. Both are two-dose vaccines. While the full efficacy of Covaxin is yet to be determined, it was given go-ahead by the DCGI citing 'public interest'. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR). Public health experts believe that intranasal vaccines for coronavirus, administered through the nose rather than muscles, can be a potential gamechanger in India's fight against the coronavirus pandemic. Last month, Pune-based Serum Insititute of India and Codagenix Inc had announced that they have received regulatory approval in the UK to begin an early-stage trial of their single-dose, intranasal coronavirus vaccine. SEE ALSO: <a href="https://www.businessinsider.in/budget/news/indian-government-budget-dilemma-curb-the-sale-of-cigarettes-or-let-the-over-12-billion-tobacco-industry-provide-the-much-needed-cash/articleshow/80340422.cms">Indian government’s budget dilemma – curb the sale of cigarettes or let the over $12 billion tobacco industry provide the much needed cas</a> <a href="https://www.businessinsider.in/business/startups/news/zoom-dropbox-backer-salesforce-ventures-makes-its-first-investment-in-india-in-hr-tech-startup-darwinbox-which-claims-to-have-grown-by-200-during-lockdown/articleshow/80341562.cms">Zoom, Dropbox backer Salesforce Ventures makes its first investment in India in HR tech startup Darwinbox, which claims to have grown by 200% during lockdown</a> <a href="https://www.businessinsider.in/stock-market/news/home-first-finance-company-hffc-is-set-to-launch-its-1153-crore-ipo-on-january-21/articleshow/80341439.cms?upcache=2">Warburg Pincus-backed Home First Finance Company to launch ₹1,153 crore IPO on January 21</a>

Expert panel of India's drug regulator mulling Bharat Biotech's nasal vaccine trial proposal

<ul class="summary-list"><li>A US company called Altimmune is developing a <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> that gets sprayed up the <keyword id="6374458" type="UNKNOWN" weightage="60" keywordseo="Nose">nose</keyword>.</li><li>Such intranasal vaccines may <a href="https://www.businessinsider.com/vaccines-reduce-coronavirus-transmission-early-research-2021-2">reduce coronavirus transmission</a> better than shots do.</li><li>Boosters designed to protect against variants could also be delivered intranasally, experts say.</li></ul>It's an intuitive idea: Wouldn't it be best to administer a <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> vaccine in the place it first invades the body?Altimmune, a biotech startup based in Maryland, is trying to develop a COVID-19 vaccine that gets squirted into your nose, not jabbed in your arm."Delivering vaccines to the sight of first exposure is an advantage," Dr. Buddy Creech, who directs the Vanderbilt University vaccine-research program and has <a href="https://jamanetwork.com/journals/jama/fullarticle/2777059">worked with Altimmune</a>, told Insider. "Typically, you don't get COVID-19 in the deltoid muscle of your arm - you get it in your nose, eyes, and throat. So it makes sense we'd want to at least consider a vaccine that can generate some immunity in mucosal orifices."The three COVID-19 vaccines authorized in the US are, of course, all shots. Though they appear to curb transmission, it's unlikely that they <a href="https://www.businessinsider.com/vaccines-reduce-coronavirus-transmission-early-research-2021-2">stop it</a>. An intranasal vaccine could create an extra line of defense, since it would prompt the immune system to produce antibodies that block infection locally in the mucous membranes of your nose and throat. That would prevent transmission by stopping viral shedding from those orifices.Altimmune last month launched <a href="https://clinicaltrials.gov/ct2/show/NCT04679909?intr=adcovid&amp;spons=altimmune&amp;draw=2&amp;rank=12&amp;rank=1">a 180-person trial</a> of its intranasal vaccine, called AdCOVID, to test how safe the vaccine is, what side effects it prompts, and what levels of antibodies and T-cells it produces. Participants range in age from 18 to 55. The company expects to have data in the second quarter of this year.<div type="image" title="intranasal COVID 19 vaccine candidate AdCOVID" height="2480" width="3306" msid="81355356" hostid="261"></div>Scot Roberts, the chief scientific officer at Altimmune, told Insider that the best-case scenario would be a rollout to adults at the end of this year or in early 2022.Other intranasal vaccine candidates are being tested in <a href="https://www.europeanpharmaceuticalreview.com/news/129563/phase-i-trial-of-intranasal-covid-19-vaccine-spray-approved-in-china/">China</a>, <a href="https://health.economictimes.indiatimes.com/news/pharma/bharat-biotech-to-start-phase-1-trials-of-covid-19-intranasal-vaccine-in-feb-march/80166695">India</a>, and the <a href="https://www.biopharma-reporter.com/Article/2021/01/11/Needle-free-COVID-19-vaccine-COVI-VAC-enters-Phase-1-trials">UK</a>.<h2>A nasal spray could prevent viral shedding from noses and throats</h2><h2><div type="image" title="Altimmune" height="2989" width="3986" msid="81355358" hostid="261"></div></h2>AdCOVID wouldn't be the first vaccine that doesn't require a needle. The polio vaccine was first swallowed as pill, and the Centers for Disease Control and Prevention has approved multiple nasal-spray flu vaccines.Vaccines injected into the arm muscle, however, are most common. These prompt your immune system to start producing T-cells that remember the pathogen, should it ever return, and antibodies that fight off the virus across your body - what's known as systemic immunity.But those antibodies don't always flood into the mucus-covered surfaces of the nose and throat (where a respiratory virus likes to hang out) in large enough numbers to stop the virus from replicating there.A nasal spray can prompt your immune system to create antibodies known as immunoglobulin A locally in your mucosal orifices, said Dr. Paul Goepfert, the director of the Alabama Vaccine Research Clinic."It's possible that this would be a much more efficient vaccine to reduce <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> spread," Goepfert told Insider.Altimmune found in a <a href="http://www.biorxiv.org/content/10.1101/2020.10.10.331348v1">recent animal study</a> that its intranasal COVID-19 vaccine prompted both systemic immunity and mucosal immunity. <a href="https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0#%20">Two</a> <a href="https://science.sciencemag.org/content/early/2021/02/16/science.abf4896">other</a> animal studies found that an intranasal spray prevented infections while almost completely blocking coronavirus transmission.<h2>Nasal sprays could serve as boosters to target coronavirus variants</h2><div type="image" title="vaccine shot" height="1335" width="2000" msid="81355359" hostid="261"></div>A proliferation of coronavirus variants has raised concerns that existing vaccines will need to be reinforced via booster shots. Pfizer and Moderna are <a href="https://www.businessinsider.com/moderna-nih-test-booster-shots-covid-19-variants-2021-2">testing new versions of their shots</a> to combat such variants, but distributing them could be another enormous undertaking.A key advantage of Altimmune's spray is that it doesn't require refrigeration and can be kept at room temperature for months."If we do need revaccinations or to top up immunity in the presence of a variant, this approach makes perfect sense," Roberts said.Daniel Oran and Eric Topol, two COVID-19 researchers at the Scripps Research Translational Institute in California, have said intranasal vaccines could help, since people might be able to administer the vaccines themselves."Simply mailing someone a nasal spray is far more convenient than arranging for an in-person injection," they <a href="https://www.scientificamerican.com/article/to-beat-covid-we-may-need-a-good-shot-in-the-nose/">wrote in Scientific American</a> on Monday. They also pointed out that swapping a needle for a spray could encourage more people to get vaccinated in the first place.<h2>Altimmune hopes to test its spray in children this year</h2><div type="image" title="intranasal vaccine h1n1 flu" height="2000" width="3000" msid="81355364" hostid="261"></div>Altimmune plans to test its intranasal vaccine in children and is talking to the Food and Drug Administration about how to formulate those pediatric trials. The company hopes to launch a trial among children while the drug is still being tested in adults.None of the COVID-19 vaccines authorized in the US can be administered to children younger than 16, since the companies didn't include kids in their early trials."Kids don't get so sick, but they sure can spread the virus. So this idea of mucosal immunity that blocks transmission is really a perfect fit for the pediatric population," Roberts said. "Clearly the FDA recognizes the need. We can't leave 70 million Americans on the side, unvaccinated."Goepfert said that developing a nasal-spray vaccine for children would be a win-win: It would stymie their capacity for transmission and make it easier to vaccinate them."Not having to stick somebody is particularly appealing for pediatricians," he said.

A future COVID-19 vaccine could be squirted up the nose. The nasal spray could stop transmission, especially in kids.

Hello,Today in <keyword id="6354525" type="UNKNOWN" weightage="100" keywordseo="healthcare">healthcare</keyword> news: <a href="https://www.businessinsider.com/digital-health-startups-like-ro-are-distributing-covid-19-vaccines-2021-3">Startups want in on vaccination efforts</a>, <a href="https://www.businessinsider.com/intranasal-covid-19-vaccine-spray-could-stem-spread-2021-3">the potential of an intranasal vaccine</a>, and <a href="https://www.businessinsider.com/whats-in-the-biden-covid-stimulus-checks-tax-credits-unemployment-3">what's in the stimulus bill the Senate passed this weekend</a>. <a href="https://www.businessinsider.com/digital-health-startups-like-ro-are-distributing-covid-19-vaccines-2021-3"></a><h3><a href="https://www.businessinsider.com/digital-health-startups-like-ro-are-distributing-covid-19-vaccines-2021-3">Digital health startups like Ro and Zocdoc want in on the US vaccination effort. They're wading into a complex vaccine distribution puzzle.</a></h3><ul><li>Digital health startup <keyword id="179072" type="ORGANIZATION" weightage="60" keywordseo="RO">Ro</keyword> said Wednesday that it was offering in-home COVID-19 vaccinations to currently eligible residents of Yonkers, New York.</li><li>The effort is fully funded by donations and corporate sponsorships.</li><li><a href="https://www.businessinsider.com/digital-health-startups-like-ro-are-distributing-covid-19-vaccines-2021-3">Other startups like Zocdoc have similarly expressed interest in helping local governments roll out vaccination efforts to patients that are otherwise hard to reach.</a></li></ul><a href="https://www.businessinsider.com/digital-health-startups-like-ro-are-distributing-covid-19-vaccines-2021-3">Read the full story from Megan Hernbroth here&gt;&gt;</a><h3><a href="https://www.businessinsider.com/intranasal-covid-19-vaccine-spray-could-stem-spread-2021-3"><div type="image" title="flumist intranasal flu vaccine" height="2657" width="3554" msid="81395982" hostid="261"></div></a></h3><h3><a href="https://www.businessinsider.com/intranasal-covid-19-vaccine-spray-could-stem-spread-2021-3">A future COVID-19 vaccine could be squirted up the nose. The nasal spray could stop transmission, especially in kids.</a></h3><ul><li>A US company called Altimmune is developing a COVID-19 <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> that gets sprayed up the nose.</li><li>Such intranasal vaccines may reduce <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> transmission better than shots do.</li><li><a href="https://www.businessinsider.com/intranasal-covid-19-vaccine-spray-could-stem-spread-2021-3">Boosters designed to protect against variants could also be delivered intranasally, experts say.</a></li></ul><a href="https://www.businessinsider.com/intranasal-covid-19-vaccine-spray-could-stem-spread-2021-3">Read the full story from Aylin Woodward and Allison DeAngelis here&gt;&gt;</a><h3><a href="https://www.businessinsider.com/whats-in-the-biden-covid-stimulus-checks-tax-credits-unemployment-3"><div type="image" title="Senate Majority Leader Chuck Schumer" height="1334" width="1778" msid="81395983" hostid="261"></div></a></h3><h3><a href="https://www.businessinsider.com/whats-in-the-biden-covid-stimulus-checks-tax-credits-unemployment-3">11 things you need to know about the revised COVID stimulus bill Senate Democrats just passed</a></h3><ul><li>The Senate passed Biden's $1.9 trillion stimulus package.</li><li>They've made several changes since the House passed the bill last week.</li><li><a href="https://www.businessinsider.com/whats-in-the-biden-covid-stimulus-checks-tax-credits-unemployment-3">Biden's proposal to raise the hourly minimum wage to $15 didn't make the cut. </a></li></ul><a href="https://www.businessinsider.com/whats-in-the-biden-covid-stimulus-checks-tax-credits-unemployment-3">Read the full story from Kimberly Leonard here&gt;&gt;</a>More stories we're reading:<ul><li><a href="https://www.businessinsider.com/detroit-mayor-coronavirus-vaccine-johnson-and-johnson-moderna-pfizer-2021-3">Detroit's mayor reportedly said J&amp;J's vaccines aren't as good, so he said declined the city's first shipment</a> (Insider)</li><li><a href="https://www.bloomberg.com/news/articles/2021-03-05/unitedhealth-s-deal-machine-scoops-up-covid-hit-doctor-groups">UnitedHealth is scooping up doctors that have been hit hard by the pandemic</a> (Bloomberg)</li><li><a href="https://www.insider.com/covid-19-vaccines-black-market-may-be-real-report-says-2021-3">Real COVID-19 vaccine shots are being sold on the black market for up to $1,200 a dose, a study finds</a> (Insider)</li><li><a href="https://www.seattletimes.com/business/amazon/amazons-telehealth-arm-quietly-expands-to-21-more-states/">Amazon's medical provider has filed paperwork in 21 states now</a> (Seattle Times)</li></ul>- Lydia

Startups want to help vaccinate

Leading vaccine maker <keyword id="149108" type="COMPANY" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> on Wednesday announced a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp-adenovirus, single dose intranasal vaccine for Covid-19. The Hyderabad-based company owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University's Vaccine &amp; Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. According to Bharat Biotech, this intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal ‘Cell' and in an editorial in ‘Nature'. "We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive," said Krishna Ella, Chairman and Managing Director of Bharat Biotech. "Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against Covid-19 reaches all citizens of the world," he added. David T. Curiel, Director of Biologic Therapeutics Center and Professor of Radiation Oncology at Washington University School of Medicine in St. Louis and Precision Virologics Interim CEO said that the ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration. "An effective nasal dose not only protects against Covid-19, but it also prevents the spread of the disease by offering another kind of immunity that occurs primarily in the cells that line the nose and throat. Most other vaccine candidates currently under development can't do that," he said. This vaccine expands Bharat's portfolio of vaccines that are currently being developed and are in various stages of clinical development including Covaxin which is currently in Phase II human clinical trials in India, the company said. <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-jio-share-price-is-twice-as-valued-as-bharti-airtel-stock-while-vodafone-idea-vi-ranks-third/articleshow/78269261.cms">Reliance Jio is now twice as valued as Airtel that is down 25% from its peak in May</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/defense/news/china-has-hardened-its-stance-experts-decode-the-india-china-joint-statement-on-border-tensions/articleshow/78270081.cms">China has hardened its stance — experts decode the India-China joint statement on border tensions</a>

Bharat Biotech partners with Washington varsity for intranasal COVID-19 vaccine

<ul><li>Altimmune fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's new drug application for AdCOVID, an intranasal <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> candidate.</li><li>Despite the clinical hold, Altimmune said it does not anticipate a significant impact to its clinical development timeline for the vaccine candidate.</li><li><a href="https://www.businessinsider.com/?hprecirc-bullet?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">Visit Business Insider's homepage for more stories</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/alt-stock">Altimmune</a>, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the <a href="https://www.globenewswire.com/news-release/2020/12/23/2150256/0/en/Altimmune-Provides-an-Update-on-its-Investigational-New-Drug-Application-for-a-Phase-1-AdCOVID-Clinical-Trial.html">FDA issued a clinical hold</a> on the company's <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> vaccine candidate.AdCOVID is a single-dose intranasal COVID-19 vaccine candidate in early stages of development by Altimmune. The FDA has requested certain protocol modifications and submission of additional chemistry, manufacturing and controls data.Altimmune has responded to the FDA's clinical hold letter and at this point does not anticipate a significant impact to its overall development timeline for the vaccine candidate.Altimmune has surged 557% year-to-date as of Wednesday's close as investors bid up potential COVID-19 vaccine developers.Read more: <a href="https://www.businessinsider.com/investing-strategy-brexit-uk-equities-fund-managers-market-strategists-2020-12?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">From Wall Street heavyweights to boutique investment firms, we break down what 7 fund managers and market strategists think about Brexit as the 'midnight hour' approaches</a><div type="image" title="alt.JPG" height="689" width="841" msid="79943382" hostid="261"></div>

Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10%

<keyword id="15862275" type="General" weightage="20" keywordseo="Bharat-Biotechs-intranasal-Covid-vaccine" source="Orion">Bharat Biotech's intranasal Covid vaccine</keyword> has been approved by the Union Health Ministry for inclusion in the vaccination programme as a booster dose for those above 18 years of age, official sources said on Thursday. The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening, they said. The <keyword id="383216" type="General" weightage="20" keywordseo="nasal-vaccine" source="Orion">nasal vaccine</keyword> -- BBV154 -- received approval of the Drugs Controller General of India in November for restricted use in an emergency situation for those above 18 as a heterologous booster dose. The approval for the vaccine comes amid a spurt in <keyword id="8764262" type="General" weightage="100" keywordseo="covid" source="Orion">Covid</keyword> cases in China and some other countries. Prime Minister Narendra Modi had on Thursday cautioned people against complacency and urged them to wear masks in crowded places, while also directing officials to strengthen surveillance measures, especially at international airports. SEE ALSO: <a href="https://www.businessinsider.in/international/news/police-officers-were-seen-guarding-a-crematorium-in-beijing-amid-reports-of-overflowing-funeral-homes-due-to-a-resurgence-in-covid-infections-bloomberg/articleshow/96369408.cms">Police officers were seen guarding a crematorium in Beijing amid reports of overflowing funeral homes due to a resurgence in COVID infections: Bloomberg</a> <a href="https://www.businessinsider.in/india/news/pm-modi-to-review-covid-19-situation-at-high-level-meeting-today/articleshow/96417240.cms">PM Modi to review Covid-19 situation at high-level meeting today</a> <a href="https://www.businessinsider.in/science/health/3-cases-of-omicron-subvariant-bf-7-driving-chinas-covid-surge-detected-in-india/articleshow/96397261.cms">3 cases of Omicron subvariant BF.7, driving China's Covid surge, detected in India</a>

Bharat Biotech's intranasal Covid vaccine approved by govt, to be available on CO-WIN

<ul class="summary-list"><li>COVID-19 vaccines are great at preventing severe illnesses and death.</li><li>But they don't always stop transmission or mild cases.</li></ul>If we could vaccinate your nose, there's a good chance we'd be able to end this pandemic right now.But the COVID-19 shots available in the US can't control everything that happens in your nostrils. If they did, they might be able to stop all transmission of the virus that happens through our talking, singing, laughing, breathing, and sneezing around each other. If successful, a new kind of vaccine - a nasal mist that requires no needle - promises to do all that by providing the special kind of <keyword id="11893194" type="UNKNOWN" weightage="60" keywordseo="coronavirus" source="Orion">coronavirus</keyword> immunity people need to stop shuttling this virus around. "An intranasal vaccine could help bring an end to the pandemic and help give us true control over SARS-CoV-2 by limiting infection and transmission," said Marty Moore, the CEO of Meissa Vaccines. "We shouldn't settle for a new normal. We can get back to the old normal."For now, that idea remains one that needs much more robust clinical data behind it to become a reality that we could all sniff up. But the prospect is still quite exciting to many immunologists around the world.<h2>Shots in the arm aren't always great at preventing the sniffles </h2>One big reason vaccine breakthrough infections happen is because the injectable COVID-19 vaccines have been designed to give a person's body good systemic immunity against the virus, protecting internal organs such as the lungs and the heart from severe infection. But a shot in the arm can't do as much for your nose in the long run. If a vaccinated person is exposed to COVID-19, they may still get a case of the sniffles, or a flu-like COVID-19 illness. This is because they haven't developed great <a href="https://medlineplus.gov/ency/article/002264.htm">mucosal</a> immunity against the coronavirus. In other words: They're still susceptible to infection via the vulnerable <a href="https://www.ncbi.nlm.nih.gov/books/NBK27169/">moist tissues</a> that interact with the outside world, such as those in the nose, eyes, and mouth."Very early on during that honeymoon initially after vaccination when your neutralizing antibodies are at their highest, you get a bit of a spillover effect into the upper airway," <a href="https://twitter.com/celinegounder?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor">Dr. Céline Gounder</a>, an infectious-disease specialist at Bellevue hospital in New York, said at the recent IDWeek <a href="https://idweek.org/">infectious-disease conference</a>, explaining the issue of lacking durable mucosal immunity after vaccination. Meissa is one of a few smaller companies pursuing COVID-19 nasal vaccines in early-stage human trials. Codagenix, another US company, has also announced some promising (but extremely small) <a href="https://www.prnewswire.com/news-releases/codagenix-announces-safety-and-immunogenicity-data-from-phase-1-covid-19-intranasal-vaccine-trial-and-intent-to-progress-to-phase-23-studies-301382120.html?tc=eml_cleartime">early trial results</a>. Other nasal vaccines are being developed around the world, with ongoing trials in Israel, Russia, Cuba, India, Hong Kong, and Iran."Our aim is to be the transmission-blocking COVID vaccine," Moore said. <h2>Immunologists are excited about the prospect of nasal vaccines - both for unvaccinated people and as boosters</h2>Meissa's early clinical data (which the company said it would share in more detail at an upcoming immunotherapy conference in late November and early December) indicated that unvaccinated patients who are given a couple drops of Meissa's vaccine in each nostril have average mucosal antibody levels slightly higher than those measured in people with natural immunity to the virus.This suggested that Meissa's vaccine could potentially work well at preventing peskier sniffly infections, not just the COVID cases that land people in the hospital."It suggests that we can deliver immunity that's like natural infection, but we can do it safely," Moore said.This prospect has many immunologists quite excited, not only because nasal vaccines could be offered to vaccine-hesitant people who don't like shots but also because they might, perhaps, be used as boosters to top up the already very good systemic immunity people have gotten from injectable vaccines. Meissa's initial human trial is still ongoing, with 70 participants in it so far. It's only in phase 1, meaning any approval or even emergency authorization for this type of vaccine is many months and likely several thousand more volunteer participants away, at best.But so far, the results look good. Meissa, which is conducting much of its research in Kansas, said there were many reasons people have chosen to join their early-stage trial. "Sometimes it's people who are Ph.D.s or highly educated, who see the benefit of an intranasal to prevent infection itself," Moore said. "And oftentimes, it's people who just don't want a shot. They don't want something injected into them."Common side-effect complaints after Meissa's nasal vaccine so far have included runny noses, coughs, sore throats, and headaches. But the company said that no worrisome safety signals had surfaced with the vaccine, which uses a <a href="https://www.meissavaccines.com/technology">live-attenuated RSV platform to deliver</a> the coronavirus' characteristic spike protein to vaccines without risking the coronavirus itself spreading from them."There are quite a few people who would rather have drops in the nose than the needle," Moore said. "So I think an intranasal vaccine could reach not all, but many vaccine-hesitant people."

A nasal COVID-19 vaccine could be the solution to ending the pandemic, experts say, and early trial data looks promising

<ul class="summary-list"><li>A COVID-19 vaccine mist has been approved for use as a booster dose in China.</li><li>The vaccine maker CanSino repackaged its shot as a mist meant to be inhaled.</li></ul>Just one breath of a vaccine mist can provide strong immune protection against COVID-19, vaccine maker CanSino said in a <a href="https://www.cansinotech.com/html/1///179/180/1100.html">news release</a> Sunday.Regulators in China approved a COVID-19 vaccine mist for use as a booster dose, making it the first alternative to injectable vaccines used during the pandemic.The inhaled vaccine contains the same ingredients as the jabs used in China, but a nebulizer machine turns it from liquid into an aerosol spray.Similar to the COVID-19 vaccines used in the US, CanSino's formulation contains pieces of genetic material so the body can recognize the virus. While the Moderna and Pfizer vaccines introduce that material directly, the CanSino vaccine uses a <a href="https://cen.acs.org/pharmaceuticals/vaccines/Adenoviral-vectors-new-COVID-19/98/i19">harmless version of the common cold virus</a> to carry information about the coronavirus. The single-dose CanSino shot is about 92% effective at preventing severe disease due to COVID-19, and about 58% effective at preventing illness entirely, according to data reported by the <a href="https://www.who.int/news-room/feature-stories/detail/the--cansino-biologics-ad5-ncov-s--recombinant---covid-19-vaccine--what-you-need-to-know">World Health Organization</a>. Clinical trials of the mist as a booster (following a single injected dose of the vaccine) showed it was about as effective as the <a href="https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know">two-dose vaccine</a> that's widely used in Asia and abroad.The nasal mist may bolster protection in the lining of the nose and upper airways, where the virus typically enters the body, according to the press release.Other vaccines have been repackaged as mists before, such as the <a href="https://www.flumistquadrivalent.com/">FluMist</a> intranasal vaccine seen in pediatricians' offices every flu season. Inhaled vaccines provide a needle-free alternative for kids and adults alike, but <a href="https://www.ncbi.nlm.nih.gov/search/research-news/8905">evidence from past flu seasons</a> has shown that the mist doesn't always achieve the same level of efficacy as a shot.Only time will tell if the mistable COVID vaccine provides enough booster protection to be approved and widely distributed in other countries.

China approved a COVID-19 vaccine mist that can be inhaled: the first needle-free booster option

The Centre on Thursday announced the "Cervavac", <keyword id="3658" type="General" weightage="80" keywordseo="india" source="Orion">India</keyword>'s first indigenously-developed <keyword id="24209" type="General" weightage="100" keywordseo="vaccine" source="Orion">vaccine</keyword> for prevention of cervical cancer, will be launched in the next few months and will be available in the price range of Rs 200-Rs 400. Cervical cancer ranks as the 2nd most prevalent cancers in India and accounts for nearly one-fourth of the world's cervical cancer deaths despite being largely preventable. As per current estimates, every year, approximately 1.25 lakh women are diagnosed with cervical cancer, and over 75,000 die from the disease in India, and 83 per cent of invasive cervical cancers are attributed to HPVs 16 or 18 in India, and 70 per cent of cases worldwide. Announcing the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in presence of Adar C. Poonawalla, CEO, <keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword> and other prominent scientists and dignitaries, Union Science &amp; Technology Minister Jitendra Singh said that this affordable and cost-effective vaccine marks an important day for the DBT and the BIRAC as it takes India a step closer to PM Narendra Modi's vision of Atmanirbhar Bharat. He noted that the most promising intervention for preventing cervical cancer is vaccination against human papillomavirus (<keyword id="102327" type="General" weightage="50" keywordseo="hpv" source="Orion">HPV</keyword>). It is estimated that HPV types 16 and 18 (HPV-16 and HPV-18) together contribute to approximately 70 per cent of all invasive cervical cancer cases worldwide. The first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) vaccine will be launched in few months, Poonawalla said, adding that the vaccine will be available to the people in an affordable price range of Rs 200-400. Poonawalla, in his brief address, said that the wellbeing and protection of mother and child is the core philosophy of <keyword id="242973" type="General" weightage="50" keywordseo="serum-institute" source="Orion">Serum Institute</keyword> as only a healthy India can be a productive India. Jitendra Singh pointed out that within a year of implementation, the Mission Covid Suraksha demonstrated major achievements such as development of the world's first DNA vaccine for Covid-19 by Cadila Healthcare which received Emergency Use Authorisation on August 20, 2021, and supporting the development of the nation's first mRNA Vaccine and intranasal vaccine candidate against Covid-19. He said that "Cervavac" is an outcome of a partnership of the DBT and the BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India for the indigenous development of quadrivalent vaccine through its partnership programme 'Grand Challenges India'

You Searched For "intranasal vaccine" and got 9 results

Expert panel of India's drug regulator mulling Bharat Biotech's nasal vaccine trial proposal

IANS

A future COVID-19 vaccine could be squirted up the nose. The nasal spray could stop transmission, especially in kids.

Aylin Woodward,Allison DeAnge…

Startups want to help vaccinate

Lydia Ramsey Pflanzer

Bharat Biotech partners with Washington varsity for intranasal COVID-19 vaccine

Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10%

Matthew Fox

Bharat Biotech's intranasal Covid vaccine approved by govt, to be available on CO-WIN

PTI

A nasal COVID-19 vaccine could be the solution to ending the pandemic, experts say, and early trial data looks promising

Hilary Brueck

China approved a COVID-19 vaccine mist that can be inhaled: the first needle-free booster option

Andrea Michelson

India to launch its first indigenously developed cervical cancer vaccine in the next few months

IANS

Popular Keywords

Buying Guides